MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation
Cannabis Law Report
OCTOBER 26, 2021
Studies estimate that the number of people suffering from rheumatoid arthritis may rise to over 78 million by 2040. MYMD-1’s primary purpose is to slow the aging process and extend healthy lifespan, and it is also showing promise as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-prolific therapeutic.
52 
Let's personalize your content